Jue He, MD, PhD

Dr. Jue He is an Assistant Professor in the Department of Psychiatry, University of Manitoba. Dr. He received his MD in Suzhou University, China and PhD in Neuropsychopharmacology at Nagoya University, Japan. Dr. He completed 6 years of postdoctoral training in the Department of Psychiatry at University of Saskatchewan and half year in Tokyo Metropolitan Institute for Neuroscience. Dr. He began his academic career at University of Manitoba as Assistant Professor in 2009.

Dr. He’s research interests are primarily neuropsychiatry. His research uses animal models such as Alzheimer’s disease (AD) transgenic mouse model to examine the mechanism of learning and memory, and to investigate the beneficial effects and related mechanism of atypical antipsychotics and antidepressants in AD treatment using molecular and behavioural assessment techniques. He assesses learning ability, anxiety-, depression- and schizophrenia-like behavioural in mice and rats in his behavioural laboratory. He also studies the mechanism of schizophrenia in a phencyclidine-induced animal model. His work includes research collaborations in North America and China.

Dr. He has received research support from Canadian Institute of Health Research (CIHR), Canadian Psychiatric Research Foundation (CPRF), Manitoba Medical Service Foundation, Health Science Centre Foundation, as well as the University of Manitoba.

---

Selected Publications:

1. Yu Y, He J, Zhang Y, Luo H, Zhu S, Yang Y, Zhao T, Wu J, Huang Y, Kong J, Tan Q, Li XM (2009) Increased hippocampal neurogenesis in the progressive stage of Alzheimer’s disease phenotype in an APP/PS1 double transgenic mouse model. Hippocampus, 19:1247-1253. (Yu Y and He J contributed equally to this work).

2. He J, Luo H, Yan B, Yu Y, Wang H, Wei Z, Zhang Y, Xu H, Tempier A, Li X, Li X-M (2009). Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer’s disease. Neurobiol Aging, 30:1205-1216.

3. He J, Kong J, Tan Q, Li X, Li XM (2009). Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models. Cell Adhesion & Migration 3(1):129-137.

4. He J, Yang Y, Yu Y, Li X, Li X-M (2006). The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav Brain Res, 172:39-45.

5. He J, Xu H, Yang Y, Rajakumar D, Li X, Li X-M (2006). The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res, 168:236-242.

6. He J, Yang Y, Xu H, Zhang X, Li X-M (2005). Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacology, 30:1511-1520.

7. He J, Xu H, Yang Y, Zhang X, Li X-M (2005). Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav Brain Res, 160:178-187.

8. He J, Xu H, Yang Y, Zhang X, Li X-M (2004). Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats. Brain Res, 1018:186-192.

9. He J, Yamada K, Nabeshima T. (2002). A role of Fos expression in the CA3 region of the hippocampus in spatial memory formation in rats. Neuropsychopharmacology, 26:259-268.

10. He J, Yamada K, Zou L, Nakajima A, Kamei H, Nabeshima T. (2002). Learning and memory in two different reward tasks in a radial arm maze in rats. Behav Brain Res, 134:139-148.